SPARK (TAVO+CXCL9) / OncoSec, Roswell Park - LARVOL DELTA

Let’s Talk About Gene Therapy for Inherited Retinal Diseases (Retina Today) - "Allen C. Ho, MD: It has been almost 4 years since the approval of the first-in-human gene therapy, the first and only pharmacologic treatment for an inherited retinal disease (IRD), and the first AAV vector therapy approved in the United States: voretigene neparvovec (Luxturna, Spark) for Leber congenital amaurosis (LCA) caused by biallelic RPE65 mutations. But our other patients with IRDs are counting the days to the approval of the next therapy."

Media quote